AstraZeneca PLC / Almirall S.A. (respiratory franchise)

Chronic Obstructive Pulmonary Disease (COPD)

$11.9B US COPD prescription drug spend, annual (CDC)

Disease Overview

COPD is a progressive obstructive lung disease driven primarily by long-term tobacco exposure and characterized by airflow limitation, exacerbations, and accelerated lung-function decline. Roughly 16 million US adults carry a diagnosis and another estimated 8-10 million remain undiagnosed, making it one of the largest chronic respiratory burdens and the leading cause of hospital readmissions in the elderly.

Competitive Landscape

When AstraZeneca acquired Almirall's respiratory franchise in July 2014, the COPD maintenance market was anchored by Boehringer Ingelheim's Spiriva (tiotropium, once-daily LAMA, ~$2.5B in 2011 sales), GSK's Advair/Breo Ellipta (ICS/LABA), and AstraZeneca's own Symbicort and Pulmicort. Eklira/Tudorza (aclidinium) was a twice-daily LAMA positioned as a 'me-too' to Spiriva with a small share of long-acting inhalers (~10-12%). The strategic value lay less in aclidinium monotherapy and more in (a) Duaklir (aclidinium/formoterol LAMA/LABA fixed-dose) addressing the fast-growing dual-bronchodilator segment then dominated by GSK's Anoro Ellipta and Novartis's Ultibro/Utibron, and (b) the proprietary Genuair multi-dose dry-powder device. The deal gave AstraZeneca a complete COPD portfolio across LAMA, LAMA/LABA, ICS/LABA, and ICS-only, plus 719 Almirall employees and immediate on-market revenue. AstraZeneca later divested Eklira and Duaklir global rights to Covis Pharma in 2021-2022, signaling the assets failed to scale to AstraZeneca's portfolio thresholds.